Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4930MR)

This product GTTS-WQ4930MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNFRSF17 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001192.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 608
UniProt ID Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ4930MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11418MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ2752MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG162
GTTS-WQ8242MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HLX-06
GTTS-WQ14901MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ1509MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACE-011
GTTS-WQ16001MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ZW-25
GTTS-WQ13574MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA QAX-576
GTTS-WQ13967MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW